BIOVOTEC AS

Their core work

BIOVOTEC is a Norwegian biotech SME developing a biomaterial-based wound dressing for chronic wounds such as pressure ulcers, leg ulcers, and diabetic foot ulcers. Their product aims to improve healing outcomes while reducing treatment costs compared to existing wound care solutions. The company has progressed from early feasibility studies through product development to clinical validation and production scale-up, following the classic SME Instrument growth pathway from Phase 1 through to an Innovation Action.

What they specialise in

How they've shifted over time

BIOVOTEC shows a textbook progression from research to market. Their early work (2015-2018) focused on proving the feasibility and developing a biomaterial wound healing concept through the BIOCURE project (SME Instrument Phase 1 and Phase 2). By 2019, they shifted decisively toward clinical validation, regulatory readiness, and manufacturing scale-up with the DERMAREP project, targeting specific chronic wound types. This trajectory shows a company moving from "can we build it?" to "can we sell it?"

BIOVOTEC is heading toward market entry — their next step is likely commercial launch, CE marking, or partnership with a wound care distributor.

How they like to work

BIOVOTEC leads every project — all three H2020 grants were coordinated by them, which is typical for SME Instrument beneficiaries building their own product. Their consortia are small (5 unique partners across 3 countries), suggesting focused partnerships rather than broad networking. Working with BIOVOTEC likely means supporting their product roadmap rather than co-developing open research.

A compact network of 5 partners across 3 countries, reflecting the focused nature of SME-driven product development projects rather than large research consortia.

What sets them apart

BIOVOTEC occupies a specific niche: biomaterial-based wound care for chronic ulcers, an area with significant unmet clinical need and growing market demand due to aging populations and diabetes prevalence. Their complete SME Instrument journey (Phase 1 → Phase 2 → Innovation Action) demonstrates both EU confidence in their technology and their ability to execute across development stages. For potential partners, they offer a clear product focus backed by clinical validation work — not abstract research but a defined path to a medical product.

Highlights from their portfolio

• BIOCURE
  Spans both SME Instrument Phase 1 (feasibility) and Phase 2 (development), showing the company successfully passed EU evaluation twice for the same core technology — a competitive achievement.
• DERMAREP
  Largest single grant (EUR 886,000) as an Innovation Action focused on clinical validation and production upscaling, representing the company's most advanced and market-ready project.